China Healthwise Holdings Limited (Stock Code: 348) disclosed a forced sale of 2,646,000 shares in Yunfeng Financial Group Limited (Stock Code: 376). The average selling price was approximately HK$3.477 per share, totaling about HK$9.2 million before transaction costs between January 5 and January 6, 2026. The sale was initiated by the securities brokerage firm to settle outstanding margin balances owed by Future Empire, a wholly-owned subsidiary of China Healthwise, and reduced this balance to nil. China Healthwise reported an estimated gain of around HK$839,000 on the transaction.

Future Empire had previously disposed of 244,000 Yunfeng shares between August 20 and August 26, 2025, for roughly HK$770,000. Under the Listing Rules, both disposals together constitute a discloseable transaction for China Healthwise.

Yunfeng focuses on long-term assurance, securities brokerage, wealth and asset management, fintech, and principal investment. According to its 2024 annual report, Yunfeng recorded revenue of approximately HK$2.8 billion and net profit of around HK$778 million for that year. Its total assets stood at about HK$96.0 billion and net assets were approximately HK$15.7 billion as of December 31, 2024. After the recent forced sale, Future Empire retains 4,316,000 shares in Yunfeng.